UNH Stock Price Is Down Nearly 50% — But Smart Money Is Starting to Buy Again

Seeing the largest health insurer in the world by revenue, ranked seventh on the Fortune Global 500, lose almost half of its market value in a year is almost disorienting. The price of UNH stock, which was once as high as $606 per share, is currently at about $274. It’s not a dip. It’s a collapse. However, some of Wall Street’s most astute institutional capital has quietly begun to re-enter the market.

It was no coincidence that UnitedHealth Group grew to be worth $300 billion. Established in 1974 as Charter Med Incorporated, a small claims processing company that catered to physicians at the Hennepin County Medical Society in Minnesota, it spent fifty years acquiring, growing, and integrating until it became something truly hard to sum up in one sentence. Under the UnitedHealthcare umbrella, it provides insurance to more than 50 million Americans. Under Optum, it manages medical services.

Pharmacy benefits are owned by it. Health analytics are owned by it. It even has a bank. This company became intricately entwined with the American health care system somewhere between Eden Prairie, Minnesota, and the hallways of Washington, D.C., which is why its present difficulties seem so significant.

The story of UNH’s stock price over the last 12 months is complicated. Quarter after quarter, the company was caught off guard by the escalating costs of healthcare. Surprises, particularly costly ones, are disliked by investors. The insurer’s quarterly results were consistently disappointing, with margins shrinking and claims exceeding projections. Subsequently, there were reports of federal investigations into Medicare Advantage billing practices.

The word “overbilling,” in particular, carries a regulatory weight that unnerves institutional investors even before any charges are brought. Then, in May of last year, there was an unforeseen change in the CEO, which further complicated the already unclear situation.

The speed at which sentiment changed is difficult to ignore. Analysts who had previously set price targets higher than $400 started to discreetly reduce their estimates. Mizuho lowered its goal from $430 to $350. Jefferies dropped from $418 to $340. Morgan Stanley dropped from $411 to $409 while maintaining its “overweight” rating. Even though no one wanted to express it directly, the directional message was fairly obvious: the plot has become more intricate.

However, this is where things start to get interesting. In recent weeks, Raymond James analysts upgraded UNH to “outperform” and set a $330 price target. They did not base their reasoning solely on optimism. They highlighted what they consider to be true operational room, including the potential to reduce general and administrative costs through the use of AI tools, improved integration of previous acquisitions, and margin recovery at Optum Health that might be exceeding what the market as a whole has priced in.

Even higher, at about $364, is the consensus among analysts polled by Visible Alpha. That’s a big difference from where the stock is currently trading, and it implies that some Wall Street analysts believe the UNH stock price has moved into an area that appears to be more of an opportunity than a continuing catastrophe.

These upgrades give the impression that the worst of the story may already be reflected in the price, a sentiment that lies somewhere between contrarian conviction and cautious optimism. According to reports, billionaire investor Paul Tudor Jones recently increased his UNH stake, sending a specific message through institutional circles. People pay attention when such macro-focused investors intervene following a 50% decline.

However, it would be too simple to present this as just a tale of recovery. Regulatory and legal risks still exist. In a Medicare Advantage fraud case, the Ninth Circuit is anticipated to rule on whether UnitedHealth can assert a broad preemption defense; a negative decision could significantly increase the company’s liability exposure. The billing practices are still being investigated.

Investors would be foolish to believe that a company’s long-term cost structure can be subtly altered by these kinds of problems, which are not abstract risks hidden in footnotes.

There was some real comfort in the company’s most recent earnings. The quarter’s revenue of $113.73 billion was marginally higher than expected. The $2.11 earnings per share were marginally but significantly higher than anticipated. Over the previous year, revenue increased by 12.3%.

These are not the numbers of an existentially troubled company. These are the numbers of a business navigating a challenging shift, one in which healthcare costs are skyrocketing, regulatory scrutiny is intensifying, and the market is looking for evidence rather than assurances.

With a quarterly dividend of $2.21, the yield at current prices is 3.2%. That dividend is perhaps the most obvious indicator of management’s underlying confidence for a company this size with a payout ratio of about 67%. When companies truly think the floor hasn’t been found, they don’t increase or maintain dividends. For long-term investors who are prepared to put up with the noise, that figure might offer some support.

The tension at the core of UNH’s stock price is what makes it worth closely monitoring at this time: a fundamentally large, deeply integrated company that generates over $450 billion in revenue annually, sitting at a valuation that some believe undervalues its long-term earnings power, while facing real operational and legal challenges that are still unresolved.

The first-quarter earnings report, which is due on April 21st, will provide the next clear indication of whether Raymond James’s anticipated margin improvement story is coming to pass or if healthcare costs continue to exceed management’s control.

Nobody can say with certainty at this time whether the $274 range will ultimately prove to be the floor or merely a stopping point on the way lower. There are significantly more analysts with “buy” ratings than those with “sell” ratings. Nearly 88% of the float is still owned by institutional investors.

The company’s structure, which is expansive, acquisitive, and firmly rooted in American healthcare, is unlikely to undergo any significant changes. However, markets tend to remain skeptical for longer than anyone anticipates, and UnitedHealth still has a lot of explaining to do. The upcoming quarters will be crucial.